
U.S. RESEARCH ROUNDUP-Definium Therapeutics, Kenvue, Werner Enterprises

I'm PortAI, I can summarize articles.
Wall Street analysts have revised ratings and price targets for several U.S.-listed companies. Notable changes include Jefferies initiating coverage of Definium Therapeutics with a buy rating and a target price of $30, while Kenvue was downgraded to hold with a target price cut to $18. Other companies like Ameriprise Financial and United Rentals also saw target price adjustments. Overall, analysts are actively reassessing their positions on various stocks, reflecting changing market conditions.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.

